SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN ...
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s iohexol injection (300 ...
Hosted on MSN
Amneal gets FDA nod for Iohexol Injection
Amneal Pharmaceuticals (AMRX) has received approval from the U.S. FDA for its iohexol injection, which contains 300 mg of iodine per mL. This marks the introduction of the first generic version of GE ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Thursday that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol ...
Iohexol is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular and body cavity imaging procedures. “We are very proud to introduce the ...
The recent lockdown in Shanghai, China, has had a serious impact on GE Healthcare's primary pharmaceutical manufacturing facility for iohexol (Omipaque, GE Healthcare) iodinated contrast media (ICM), ...
Please provide your email address to receive an email when new articles are posted on . Eleven patients reported 22 reactions during intradermal testing. Nine of 11 patients displayed cross-reactivity ...
(MENAFN- GlobeNewsWire - Nasdaq) First-to-market complex injectable with expected launch in Q1 2026 BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback